1319194-56-3

Basic information

• Product Name: 6-(2-(4-chloro-3-methyl-1H-pyrazol-1-yl)-6-methylphenyl)-3-morpholinoquinolin-2-amine
• Synonyms: 6-(2-(4-chloro-3-methyl-1H-pyrazol-1-yl)-6-methylphenyl)-3-morpholinoquinolin-2-amine
• CAS NO: 1319194-56-3
• Molecular Weight: 433.94
• Mol File: 1319194-56-3.mol

Chemical Properties

• CAS DataBase Reference: 6-(2-(4-chloro-3-methyl-1H-pyrazol-1-yl)-6-methylphenyl)-3-morpholinoquinolin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2-(4-chloro-3-methyl-1H-pyrazol-1-yl)-6-methylphenyl)-3-morpholinoquinolin-2-amine(1319194-56-3)
• EPA Substance Registry System: 6-(2-(4-chloro-3-methyl-1H-pyrazol-1-yl)-6-methylphenyl)-3-morpholinoquinolin-2-amine(1319194-56-3)

Safety Data

• Hazardous Substances Data: 1319194-56-3(Hazardous Substances Data)

Upstream product

• 1319196-51-4 6-bromo-3-morpholinoquinolin-2-amine 
• 1319197-06-2 4-chloro-1-(2-iodo-3-methylphenyl)-3-methyl-1H-pyrazole 
• 1319196-52-5 3-morpholino-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-2-amine 
• 1319197-05-1 2-(4-chloro-3-methyl-1H-pyrazol-1-yl)-6-methylaniline 
• 5807-02-3 4-morpholinoacetonitrile 
• 53848-17-2 2-bromo-6-methylaniline 
• 29124-57-0 2-amino-5-bromobenzaldehyde 

Relevant articles and documents

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1, R2, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).